Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects
Authors:
Open Access
- 28 August 2014
- journal article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 12 (4) , 365-379
Abstract
Fluoxetine and other serotonin-specific re-uptake inhibitors (SSRIs) are generally thought to owe their therapeutic potency to inhibition of the serotonin transporter (SERT). However, research in our laboratory showed that it affects, with relatively high affinity the 5-HT2B receptor in cultured astrocytes; this finding was confirmed by independent observations showing that fluoxetine loses its ability to elicit SSRI-like responses in behavioral assays in mice in which the 5-HT2B receptor was knocked-out genetically or inhibited pharmacologically. All clinically used SSRIs are approximately equipotent towards 5-HT2B receptors and exert their effect on cultured astrocytes at concentrations similar to those used clinically, a substantial difference from their effect on SERT. We have demonstrated up-regulation and editing of astrocytic genes for ADAR2, the kainate receptor GluK2, cPLA2 and the 5-HT2B receptor itself after chronic treatment of cultures, which do not express SERT and after treatment of mice (expressing SERT) for 2 weeks with fluoxetine, followed by isolation of astrocytic and neuronal cell fractionation. Affected genes were identical in both experimental paradigms. Fluoxetine treatment also altered Ca2+ homeostatic cascades, in a specific way that differs from that seen after treatment with the anti-bipolar drugs carbamazepine, lithium, or valproic acid. All changes occurred after a lag period similar to what is seen for fluoxetine’s clinical effects, and some of the genes were altered in the opposite direction by mild chronic inescapable stress, known to cause anhedonia, a component of major depression. In the anhedonic mice these changes were reversed by treatment with SSRIs.Keywords
This publication has 109 references indexed in Scilit:
- Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major DepressionBiological Psychiatry, 2013
- The Glutamate–Glutamine (GABA) Cycle: Importance of Late Postnatal Development and Potential Reciprocal Interactions between Biosynthesis and DegradationFrontiers in Endocrinology, 2013
- Towards a glutamate hypothesis of depressionNeuropharmacology, 2012
- Functional significance of glycogen synthase kinase-3 regulation by serotoninCellular Signalling, 2012
- 5-HT2B receptors are required for serotonin-selective antidepressant actionsMolecular Psychiatry, 2011
- Regulation of dorsal raphe nucleus function by serotonin autoreceptors: A behavioral perspectiveJournal of Chemical Neuroanatomy, 2011
- ΔFosB in brain reward circuits mediates resilience to stress and antidepressant responsesNature Neuroscience, 2010
- Phospholipase A2 and Cyclooxygenase 2 Genes Influence the Risk of Interferon-α–Induced Depression by Regulating Polyunsaturated Fatty Acids LevelsBiological Psychiatry, 2010
- Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depressionProstaglandins, Leukotrienes and Essential Fatty Acids, 2009
- Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of maniaMolecular Psychiatry, 2008